"This document is intended for use by national immunization programme managers and immunization partners to inform the policy discussions and operational aspects for the introduction of HPV vaccine into national immunization programmes and to provide upto-date references on the global policy, as well as the technical and strategic issues related to the introduction of HPV vaccine."--Publisher's description.
"This is a general guidance document that can be used as a reference for making decisions about and planning the introduction of a vaccine into a national immunization programme. It draws from the experiences of many countries that have introduced new vaccines. This document is an update of the 2005 WHO Vaccine Introduction Guidelines and it brings together the recommendations and guidance from many recent guidelines, tools and other documents on specific aspects of immunization and on specific vaccines. It provides updated information relevant to many vaccines that are being introduced into national immunization programmes now and in the coming years, including pneumococcal conjugate, rotavirus, meningococcal A, rubella, human papillomavirus (HPV), Japanese encephalitis, and inactivated polio vaccines. For more detailed information about a specific vaccine or aspect of immunization, decision-makers and planners should consult vaccine-specific introduction guidelines and other tools developed by WHO, UNICEF and other partners. This document provides links to many of these guidelines and tools. Drawing upon recent research findings, this document also places new emphasis on the potential impact of vaccine introduction on the immunization programme and the overall health system. Suggestions are provided throughout the document on ways to minimize possible negative effects of introducing a vaccine on the immunization programme and health system, as well as ways to maximize the opportunities that a vaccine introduction can provide to strengthen these systems."--Page ii.
This document summarizes current technical and programmatic information on WHO-prequalified human papillomavirus (HPV) vaccine products in order to facilitate informed country choices for HPV vaccine introduction (or product switch within immunization programmes). Since 2009, four HPV vaccine products have been prequalified by WHO. They include two bivalent products (Cecolin®, manufactured by Xiamen Innovax Co. Ltd., and CervarixTM, manufactured by GlaxoSmithKline Biologicals), one quadrivalent product (Gardasil®, manufactured by Merck Vaccines), and one nonavalent product (Gardasil-9®, manufactured by Merck Vaccines). One bivalent product (Walrinvax®) is currently under review by WHO and one quadrivalent (Cervavac®) is nationally licensed. The primary objective of this document is to provide comprehensive information on HPV vaccine products, including scientific evidence, vaccine pricing, presentations, cold chain and storage requirements and more. This information enables countries to compare different HPV vaccine products and make informed decisions regarding the inclusion of HPV vaccine in their national immunization programmes.
This practical guide contains seven modules targeted at district and health facility staff. It intends to meet the demands to improve immunization services so as to reach more infants in a sustainable way, building upon the experiences of polio eradication. It includes materials adapted from polio on planning, monitoring and use of data to improve the service, that can be used at any level. Revising the manual has been a team exercise. There are contributions from a large number of experts, organizations and institutions. This new edition has seven modules. Several new vaccines that have become more readily available and used in recent years have been added. Also the section on integration with other health interventions has been expanded as exciting opportunities and experiences have become evident in the years following the previous edition. Module 1: Target diseases and vaccines Module 2: The vaccine cold chain Module 3: Ensuring safe injections Module 4: Microplanning for reaching every community Module 5: Managing an immunization session Module 6: Monitoring and surveillance Module 7: Partnering with communities.
"Cervical cancer is the 2nd most common cancer affecting women by age-standardized rate (ASR) for incidence and more than 85% of the global disease burden is in developing countries. The availability of HPV vaccines as a new approach to successfully fight cervical cancer has generated substantial excitement and enthusiasm for introducing the vaccine. As of the end of 2011, 40 countries had introduced HPV vaccine in their national immunization schedule. Global experience with HPV vaccine delivery to its target population of 9-13 year old girls remains limited, particularly in resource-poor settings. Furthermore, there are many stakeholders and partners for HPV vaccine introduction and cervical cancer prevention who are new to immunization and are not the traditional child health partners of immunization programmes, but who bring experience from the fields of reproductive health, adolescent health, school health, cancer control, HIV prevention, and women's health. In this complex context, there is a need to optimally coordinate the energy, advocacy, and resources of the many stakeholders and partners so that critical vaccine delivery issues are addressed and so that countries can best benefit from the new opportunity that HPV vaccine can offer. This report summarizes key points from presentations and plenary discussions at the meeting. Priorities for action are outlined in section 9. Objectives: 1. To share an update on HPV vaccine introduction issues and the activities of key partners and stakeholders. 2. To determine outstanding questions that need to be addressed for optimal HPV vaccine delivery in countries. Outcomes: 1. A shared vision among public-private partners on short-, medium-, and long-term priorities for HPV activities. 2.A set of prioritized operational research issues that would facilitate HPV vaccine delivery. 3.A mapping of partner efforts and resources to support HPV vaccine introduction."--Page 2.
The seventh edition of the Canadian Immunization Guide was developed by the National Advisory Committee on Immunization (NACI), with the support ofthe Immunization and Respiratory Infections Division, Public Health Agency of Canada, to provide updated information and recommendations on the use of vaccines in Canada. The Public Health Agency of Canada conducted a survey in 2004, which confi rmed that the Canadian Immunization Guide is a very useful and reliable resource of information on immunization.
Most women who die from cervical cancer, particularly in developing countries, are in the prime of their life. They may be raising children, caring for their family, and contributing to the social and economic life of their town or village. Their death is both a personal tragedy, and a sad and unnecessary loss to their family and their community. Unnecessary, because there is compelling evidence, as this Guide makes clear, that cervical cancer is one of the most preventable and treatable forms of cancer, as long as it is detected early and managed effectively. Unfortunately, the majority of women in developing countries still do not have access to cervical cancer prevention programmes. The consequence is that, often, cervical cancer is not detected until it is too late to be cured. An urgent effort is required if this situation is to be corrected. This Guide is intended to help those responsible for providing services aimed at reducing the burden posed by cervical cancer for women, communities and health systems. It focuses on the knowledge and skills needed by health care providers, at different levels of care.
